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e objective here was to summarize the evidence for, and quantify the link between, serum markers of lipid metabolism and
risk of obesity-related cancers. PubMed and Embase were searched using prede�ned inclusion criteria to conduct meta-analyses
on the association between serum levels of TG, TC, HDL, ApoA-I, and risk of 11 obesity-related cancers. Pooled relative risks
(RRs) and 95% con�dence intervals were estimated using random-e�ects analyses. 28 studies were included. Associations between
abnormal lipid components and risk of obesity-related cancers when using clinical cutpoints (TC ≥ 6.50; TG ≥ 1.71; HDL ≤ 1.03;
ApoA-I ≥ 1.05mmol/L) were apparent in all models. RRs were 1.18 (95% CI: 1.08–1.29) for TC, 1.20 (1.07–1.35) for TG, 1.15
(1.01–1.32) for HDL, and 1.42 (1.17–1.74) for ApoA-I. High levels of TC and TG, as well as low levels of HDL and ApoA-I, were
consistently associated with increased risk of obesity-related cancers. e modest RRs suggest serum lipids to be associated with
the risk of cancer, but indicate it is likely that other markers of the metabolism and/or lifestyle factors may also be involved. Future
intervention studies involving lifestyle modi�cation would provide insight into the potential biological role of lipid metabolism in
tumorigenesis.
1. Introduction
Obesity is a major worldwide problem, over 30% of adults
in Western populations are obese, and there is growing
evidence of the associated health risks associated [1–5]. e
link between obesity and cancer risk has been studied exten-
sively, but the results of individual studies do not suggest
a consistent association [1, 6, 7]. Common cancers studied
in the context of obesity include colorectal, breast, prostate,
endometrial, pancreatic, liver, ovarian, kidney, gallbladder,
leukaemia, and oesophageal cancers [4, 7–17].
eunderlyingmechanisms of action are not clear [1, 18–
20]. A solid understanding could translate directly to patient
bene�t through implementation of therapeutic strategies to
reduce cancer risk andmortality [19]. Assuming that the lipid
metabolism plays a role in the biological processes driving
the development of cancer, this could be easily modi�ed
by existing methods such as exercise, medication, or diet.
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Increased physical activity levels improve cardiovascular and
overall mortality in healthy populations [21–24]. Also, phys-
ical activity aer cancer diagnosis is associated with improve-
ments in cancer outcomes [25, 26] and metabolic markers
such as cholesterol [27, 28]. As such, improvements in lipid
levels through uptake of physical activity may also translate
into improvements in cancer-speci�c survival. Experimental
evidence largely suggests that statins, a commonly used drug
to lower cholesterol levels, reduce cancer risk, though further
trials are needed [29]. However, a large meta-analysis by
the Cholesterol Treatment Trialists’ Collaboration showed no
statistically signi�cant associations between statin use and
cancer risk [30]. Nevertheless, due to heterogeneity of plasma
lipid pro�les in overweight and obese people, there may be
some inconsistency in the associations for serum lipids and
cancer risk [31]. Moreover, study populations were oen
small, insuﬃcient information was collected (e.g., lack of
BMI measurement, few lipid components measured), and
timing of blood sampling in relation to diagnosis varied
widely [32, 33]. In addition, it is thought that tissue types
are in�uenced diﬀerently by lipid components and to varying
degrees [2, 32].
With these meta-analyses, we aimed to summarize and
quantify the evidence for the link between markers of lipid
metabolism and risk of obesity-related cancers.We examined
the associations between four components of the lipid pro�le
measured in serum (total cholesterol (TC), triglycerides
(TGs), high-density lipoprotein (HDL), and apolipoprotein
A-I (ApoA)) and risk of cancers previously shown to be linked
with obesity.
2. Methods
2.1. Literature Search Strategy. We used computerised lit-
erature search databases (PubMed search followed by an
Embase search) to identify full text and abstracts pub-
lished to date. Searches were conducted both with and
without MeSH terms (“neoplasms/epidemiology,” “cancer,”
“hyperlipidemias,” “lipoproteins, HDL,” “hypertriglyceride-
mia,” “lipoproteins, apo A”). Except for English language,
human subjects, adults, and publications within the last 10
years no additional restrictions were added to the search. We
also included “grey literature,” such as letters and abstracts
presented in relevant conference meetings. All references of
the selected articles were checked, including hand searches.
2.2. Inclusion Criteria. e �nal collection of selected studies
was chosen based on the following criteria: the publication
pertained to an epidemiological study (cohort or case-control
studies), which measured the serum concentration of at least
one of the selected lipid components (TC, TGs, HDL, and
ApoA-I) prior to cancer diagnosis; the analytical methods
were well described, with suﬃcient data available; the cancers
included must have previously been linked to an increased
risk associated with obesity. ose included were colorec-
tal, breast, prostate, endometrial, pancreatic, liver, ovarian,
kidney, gallbladder, leukaemia, and oesophageal cancer [7].
To include studies with large enough power, only those
with at least 20 cancer cases were included. Initially, titles
and abstracts of articles were reviewed in order to ascertain
whether they potentially �t the inclusion criteria. If there was
doubt over whether an article met the relevant criteria, it was
subjected to a thorough assessment. Aer this �rst selection,
all articles underwent detailed evaluations of the methods
and results. Figure 1 illustrates the study exclusion process.
2.3. Data Extraction. e following details were recorded
for each study: author, year of publication, country where
the study was undertaken, serum lipid component levels
(mmol/l), study type (case-control or cohort), cancer type,
number of cases and total subjects for each level of the lipid
component(s) measured. To allow for ease of comparison, all
values in conventional units (mg/dL) were converted into SI
units (mmol/l) using conversion factors [34].
2.4. Statistical Methods. e eﬀect of each lipid component
on cancer riskwas evaluated by calculating the randomeﬀects
summary relative risk to allow for possible heterogeneity
between study results. e analyses were conducted for
dichotomized values of TC, TGs, HDL, and apoA-I). e
following clinical cutpoints were used TC ≥ 6.50; TG ≥ 1.71;
HDL ≤ 1.03; ApoA− I ≤ 1.05mmol/L, all of which mirrored
the NCEP and WHO guidelines as closely as practicable
[35–39]. Some studies presented with dichotomised serum
lipid levels, but for those that did not, participants from
each study were divided into two groups based on their
serum lipid level (“high” and “low”), and this mirrored the
NCEP and WHO guidelines as closely as practicable. A �rst
meta-analysis used all cancers from all studies. Potential
heterogeneity of the study results was assessed with weighted
forest plots, which display the relative risk estimates of cancer
risk for each lipid component. Heterogeneity of the study
results was also statistically evaluated using the 𝑄𝑄-statistic
as well as the 𝐼𝐼2 statistic [40]. Suﬃcient data allowed for an
individual analysis (using the methods described above) of
prostate, colorectal, and breast cancers. Finally, we performed
a metaregression to evaluate the eﬀect of study design (i.e
prospective cohort versus case-control studies). No other
potential confounders were included in the metaregression
due to the nature in which the data was presented through
the papers. For example, some papers acknowledge having
data for fasting status of the individuals at time of sampling,
but did not provide the actual data by individuals. Potential
publication bias and eﬀect modi�cation (by country and
year) were assessed using Begg’s Test and Egger’s funnel plot.
All analyses were performed using STATA (version 11.2).
3. Results
e initial searches produced a total of 701 articles. 33 studies
were selected for further evaluation based on information
from abstracts. Of these, 17 were excluded and a further 12
were added from hand searches and references of included
studies, giving a total of 28 studies used in the primary data
analysis. Eight studies were conducted in Asia, 12 in Europe,
and eight in theUSA (Table 1). All studies reported on at least
one of the four lipid components under investigation. e
nine included cancers were studied in associationwith cancer
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47 potentially relevant studies
27 included in primary analysis
33 potentially appropriate for inclusion
14 excluded based on abstract:
- Cancer risk not main outcome: 4
- Exposure not lipid components of 
interest: 7
- Review article: 2
- Study design: 1
17 excluded based on full article:
- Cancer risk not main outcome: 3
- Exposure not lipid components of 
interest: 3
- Insufficient data included: 10
- Diseased study population: 1
3 studies included from 
references of included studies
8 studies included from hand 
searches
703 search results 
∗NB: some studies were used in more than one analysis.
(20 for TC, 16 for TGs, 16 for HDL, and 7 for ApoA)∗
F 1
risk; all cancer diagnoses were histologically con�rmed. �f
those articles examined for inclusion, the major reasons for
exclusion were missing information on methods and statis-
tical analysis (𝑛𝑛 𝑛 𝑛𝑛), while a further three were excluded
because serum lipid components were not the exposure of
interest, and three were removed because incident cancer risk
was not the outcome variable in the analysis.
For each lipid component studied we looked at the risk
of developing cancer in those with abnormal versus normal
levels.e random-eﬀects analysis, comparing overall cancer
risk and total cholesterol level, showed a pooled eﬀects
relative risk of 1.18 (95% CI 1.08–1.29) (Figure 2). e 𝑄𝑄-
statistic and 𝐼𝐼2-statistic suggested heterogeneity (𝑄𝑄 𝑛 2𝑄𝑛𝑄𝑛2;
d𝑓𝑓 𝑛 𝑛𝑓; 𝑃𝑃 𝑛𝑃 𝑛𝑄𝑛𝑛𝑛; 𝐼𝐼2 𝑛 92𝑄𝑓%), which warranted the use
of a random-eﬀects model.e association between TGs and
overall cancer risk resulted in a pooled relative risk of 1.20
(95% CI 1.07–1.35). e pooled relative risk was 1.15 (95%
CI 1.01–1.32) when studying the association between HDL
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and risk of obesity-related cancers.e pooled eﬀects relative
risk of overall cancer was 1.42 (95%CI 1.17–1.74) for ApoA-I
(Figure 2).
We also conducted a strati�ed analysis by study type
and found that the pooled RRs for case-control studies were
slightly diﬀerent (i.e., RR (95% CI) = 0.98 (0.81–1.18)) and
(RR (95% CI) = 1.20 (1.04–1.38) for case-control and cohort
studies on TC, resp.). We investigated this further with a
metaregression, but did not �nd a statistically signi�cant
eﬀect (i.e.,𝑃𝑃 value of 0.193 when studying TC). Begg’s test did
not indicate signi�cant publication bias (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), which is
evident from the funnel plot, as there is a relatively symmetric
distribution observed among studies with small sample size
(Figure 3).
Finally, we also performed a meta-analysis speci�cally
for TC and risk of prostate, breast, and colorectal cancer.
e pooled relative risk for prostate cancer was 1.04 (95%
CI: 0.87–1.24), whereas it was 1.08 (95% CI: 0.89–1.31) and
1.20 (95% CI: 0.44–3.26) for breast and colorectal cancers,
respectively.
4. Discussion
ese meta-analyses summarize the current evidence for a
link between serum markers of lipid metabolism and risk of
obesity-related cancers. All pooled models showed evidence
for an association between abnormal lipid components and
risk of obesity-related cancers when using clinical cutpoints.
e precise aetiology of the link between obesity and
risk of cancer has yet to be determined, but there has been
growing evidence for a role of lipid metabolism in tumour
development [18]. Apart from the studies listed on the link
between serum lipids and cancer risk (Table 1), there is
also preclinical evidence. For instance, it is thought that
androgens stimulate prostate tumor growth via activation of
pathways that regulate lipogenic gene expression, resulting in
lipid accumulation [41]. Hyperlipidemia has also been shown
to be involved in colorectal tumour development and initia-
tion and progression of breast and prostate cancers [42–44].
Moreover, there is experimental evidence that fatty acid syn-
thase (FAS), the enzyme that synthesizes fatty acids de novo,
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F 3: Funnel plot of Begg’s test (with 95% CI) to quantify pres-
ence of publication bias.
is involved in tumorigenesis [45–47]. For example, prostate
cancers overexpressing FAS display aggressive behavior, with
the highest expression in patients with bony metastatic
disease [47, 48]. In addition, nutritional studies showed that
diets high in fat are linked to accelerated tumour growth and
metastasis [42, 49]. Furthermore, cholesterol-lowering drugs
such as statins have been shown to reduce the formation and
spread of metastatic cancer cells [50, 51]. Finally, the immune
system is thought to play a role in the link between HDL,
ApoA-I, and tumorigenesis [52]. ese lipid components
decrease free proin�ammatory cytokines such as tumour
necrosis factor-𝛼𝛼 (TNF-𝛼𝛼) which consequently reduces tissue
damage, in�ltration of macrophages and neutrophils, and
attenuates tumour formation [53]. erefore, low levels of
HDL andApoA-Imay contribute to an in�ammatory process
linked to tumour biology.
Recent years have seen a multitude of reviews and meta-
analyses comparing obesity and speci�c cancer risks� results
varied widely depending on the type of cancer investigated,
with relative risks ranging from 1.02 to 4.10 (breast cancer
[11, 54–56], endometrial cancer [57], pancreatic [58–60],
liver [17], prostate cancer [61], and colon and rectal cancer
[15, 16]). As a result, our �ndings for an association between
serum lipid components and risk of cancer also varied by type
of cancer, as can be seen from our results for HDL (Figure 2),
show that there may be stronger correlation between serum
HDL levels and cancer risk, dependent on cancer type.ose
results focusing on a single cancer showed more consistent
results, suggesting that even among obesity-related cancers
there may be a diﬀerent association with serum lipid levels.
4.1. Strengths and Limitations of is Study. e greatest
strength of this study is that we examined four diﬀerent com-
ponents of the lipid pro�le in relation to risk of developing
cancer in the context of obesity. We also made all possible
eﬀorts to include all relevant available publications, including
searching the two main online databases (PubMed and
Embase). Additionally, our clearly de�ned objective criteria
for exposure, outcome, and other study characteristics were
speci�ed a priori. ere was no evidence of publication bias
in these analyses.
A number of the studies subdivided levels of lipid com-
ponents, but this was not performed consistently across the
studies. Studies which had not dichotomised serum lipid
levels from the outset were divided into two groups based on
their serum lipid level (“high” and “low”) tomirror the NCEP
and WHO guidelines as closely as practicable [38, 62]. is
crude categorization may have compromised the accuracy
and resulted in miscategorising of individuals, but given the
rather small diﬀerences in cutoﬀs we do not believe that this
has had a major impact on our analyses.
Heterogeneity among studies may also arise from dif-
ferent method of assessment of serum lipids. By perform-
ing random-eﬀects analyses, we have taken into account
between-study variation. Within-person variation is a likely
interference with results as the one measurement taken may
not be representative for a person’s average, or previous
lipid levels. However, this variation will be present in all
studies using a single measurement. In addition, adjustments
made for confounding factors (e.g., gender or age) were not
consistent across included studies and some sample sizes
were relatively small or excluded one gender. Again, random
eﬀects analyses take into account this heterogeneity and in
additionwe included ametaregression analysis for study type.
In addition, the studies did not provide age-speci�c data,
so it was not possible to conduct age-speci�c meta-analyses
which presents us with a limitation. Persons younger than
middle aged more rarely have abnormal lipid pro�les and are
also considerably less likely to be diagnosed with the cancers
of interest than in those people aged over 50. us, this
leaves our study population with a relatively low probability
of having both suﬃcient exposure and number of cases in the
lower age range. We do not believe that this will have had a
major eﬀect on our results, although it is worth considering
that this may have diluted the strength of our �ndings
somewhat.
Due to the information provided in the included studies,
we had no means to adjust our analyses for cancer screening
practices. Undoubtedly, these practices vary around the
world and thus the diﬀerences could lead to the introduction
of detection bias.
Finally, the analyses of the three individual cancers
(prostate, breasts and colorectal cancers) did not produce sta-
tistically signi�cant relative risks, which most likely follows
from a lack of power due to the limited number of studies
available for inclusion. Future research, with larger sample
sizes, repeatedmeasurements, and consistent adjustments for
confounding could provide information to inform a more
reliable estimate of links between serum lipid components
and cancer risk.
4.2. Conclusions. Abnormal levels of all lipid components
studied were statistically signi�cantly associated with an
increased risk of obesity-related cancers, with the strongest
association for serum ApoA-I. Despite a suggestion for a
link between the lipid metabolism and risk of cancer, the
magnitude of the pooled relative risk was relatively small.
is may be because the studied lipid components are
markers of obesity or because they are markers of other
lifestyle factors potentially associated with tumorigenesis.
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Since lipid components are easily modi�ed through lifestyle
interventions such as diet or exercise, research into serum
lipid components and cancer risk presents a prime oppor-
tunity for intervention studies to help provide the desired
insight into their biological role.
Abbreviations
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